The PCR-based assays run on the company's Aries system, which itself received FDA clearance in October 2015.
The M1, a lower-throughput version of the company's Aries System, can process up to six samples and six assays at a time.
Luminex expects Nanosphere to contribute between $13 million and $16 million to its consolidated revenue in 2016.
Luminex's anticipated FY 2016 revenue growth of 6 percent to 9 percent could potentially push higher into the double digits following the integration of Nanosphere.
The CE marking follows the approval of the Aries sample-to-answer system and HSV assay in Europe earlier this year and in the US in late 2015.
The company raised its offer to $1.70 per share from its previous agreement of $1.35 per share in response to an unsolicited bid from a third party.
Luminex said it will pay $1.35 per share for the molecular diagnostics developer, which today reported Q1 revenues rose 43 percent year over year.
The company reported record assay and royalty revenues, and said that system revenues grew 39 percent year over year.
The software connects Luminex's FDA-cleared Aries PCR-based platform with its multiplex xMap technology-based Magpix system.
Both the system, which detects and amplifies nucleic acids, and the assay, which identifies and types HSV DNA, were approved in the US late last year.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.